IMR Press / EJGO / Volume 22 / Issue 4 / pii/2001169

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovanan carcinomas

Show Less
1 Department of Obstetrics & Gynecology; Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
2 Department of Obstetrics & Gynecology; Affiliated with Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3 Science Based Industrial Park, Ness Ziona, Israel
Eur. J. Gynaecol. Oncol. 2001, 22(4), 292–296;
Published: 10 August 2001

The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumor (BJOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC) The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53, HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p = 0.0006 and p = 0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (I 00% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p = 0.007, p = 0.0003 and p = 0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of bemgn ovanan serous cystdenomdenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, -BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.

Borderline serous ovarian tumor
Serous papillary ovarian carcinoma
Benign serous ovarian tumor
Clinical parameters
Molecular markers
Back to top